Saif, A., Verbus, E. A., Sarvestani, A. L., Teke, M. E., Lambdin, J., Hernandez, J. M., & Kirsch, D. G. (2023). A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032). Ann Surg Oncol, 30(2), 683–685. https://doi.org/10.1245/s10434-022-12762-z

Saif, Areeba, Emily A. Verbus, Amber Leila Sarvestani, Martha E. Teke, Jacob Lambdin, Jonathan M. Hernandez, and David G. Kirsch. “A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032).” Ann Surg Oncol 30, no. 2 (February 2023): 683–85. https://doi.org/10.1245/s10434-022-12762-z.

Saif A, Verbus EA, Sarvestani AL, Teke ME, Lambdin J, Hernandez JM, et al. A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032). Ann Surg Oncol. 2023 Feb;30(2):683–5.

Saif, Areeba, et al. “A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032).” Ann Surg Oncol, vol. 30, no. 2, Feb. 2023, pp. 683–85. Pubmed, doi:10.1245/s10434-022-12762-z.

Saif A, Verbus EA, Sarvestani AL, Teke ME, Lambdin J, Hernandez JM, Kirsch DG. A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032). Ann Surg Oncol. 2023 Feb;30(2):683–685.